{"nctId":"NCT01539083","briefTitle":"Velcade (Bortezomib) Consolidation After Transplant","startDateStruct":{"date":"2012-01-13","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":256,"armGroups":[{"label":"Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]","type":"EXPERIMENTAL","interventionNames":["Drug: Bortezomib","Drug: Cyclophosphamide","Drug: Dexamethasone"]},{"label":"Thalidomide + Prednisolone [TP Consolidation]","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: Prednisolone"]},{"label":"Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: Bortezomib","Drug: Prednisolone"]}],"interventions":[{"name":"Thalidomide","otherNames":[]},{"name":"Bortezomib","otherNames":[]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Dexamethasone","otherNames":[]},{"name":"Prednisolone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Previously diagnosed with multiple myeloma based on international myeloma working group (IMWG) criteria.and meet all of the following; Serum M-protein greater than or equal to (\\>=) 1 gram per deciliter (g/dL) (\\>=10 gram per liter); Urine M-protein \\>=200 milligram (mg) per 24 hour and Serum Free Light chain (FLC) assay: Involved FLC Level \\>=10 mg/dL (\\>=100 mg/L) provided serum FLC ratio is normal\n* Meet the pretreatment laboratory criteria as specified in the study protocol at and within 21 days before baseline (Day 1 of Cycle 1, before bortezomib administration for induction).\n* Have ECOG status 0-2.\n* Men and women must practice an appropriate method of birth control as specified in the study protocol from signing of the informed consent form though to the 12-month visit/early termination visit.\n\nExclusion criteria:\n\n* Has previously received treatment for multiple myeloma (including prior therapy with radiation or pulsed dexamethasone) as specified in the study protocol.\n* Has a history of any other malignancy within 5 years before enrolment as specified in the study protocol.\n* Has had major surgery as specified in the study protocol within 30 days before enrolment.\n* Had a myocardial infarction within 6 months of enrolment or has New York Heart Association (NYHA) Class III or IV heart failure (or other clinically significant cardiac medical history as specified in the study protocol).\n* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12","description":"CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\\<) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level \\<100 milligram (mg) per 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12","description":"CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\<5 percent plasma cells in bone marrow.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":null},{"groupId":"OG001","value":"44.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"53.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12","description":"sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\<5 percent plasma cells in bone marrow.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of \\>= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be \\>=0.5 gram per deciliter \\[g/dL\\]) Urine M-component and/or (the absolute increase must be \\>=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \\>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be \\>=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.05","spread":null},{"groupId":"OG001","value":"22.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (DFS)","description":"DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\<5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of \\>= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.53","spread":null},{"groupId":"OG001","value":"13.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase","description":"The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.335"},{"groupId":"OG001","value":"0.14","spread":"0.397"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.300"},{"groupId":"OG001","value":"0.05","spread":"0.296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.319"},{"groupId":"OG001","value":"0.18","spread":"0.270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.278"},{"groupId":"OG001","value":"0.05","spread":"0.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.373"},{"groupId":"OG001","value":"0.20","spread":"0.395"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.140"},{"groupId":"OG001","value":"0.00","spread":"0.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.216"},{"groupId":"OG001","value":"0.11","spread":"0.213"}]}]}]},{"type":"SECONDARY","title":"Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase","description":"Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"19.68"},{"groupId":"OG001","value":"1.0","spread":"19.69"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":88,"n":254},"commonTop":["Constipation","Peripheral Sensory Neuropathy","Nausea","Upper Respiratory Tract Infection","Fatigue"]}}}